2020 ASCO Virtual Direct™ Highlights

 

Lung
21:58

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Targeted Therapy in Early Stage EGFR+ NSCLC: Adjuvant Osimertinib, Adjuvant EGFR TKI Gefitinib vs. Standard Chemo

FEATURING Millie Das
  • 17 views
  • September 22, 2020
06:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on IO in NSCLC: Does Neoadjuvant Durvalumab Add Value to Standard Chemotherapy? Is IO Atezolizumab a Feasible and Safe Addition to SABR?

FEATURING Millie Das
  • 89 views
  • September 22, 2020
05:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on KEAP1/NFE2L2 Mutations in Localized NSCLC: Can Genotyping KEAP1/NFE2L2 Mutations Help Facilitate Treatment Personalization?

FEATURING Millie Das
  • 64 views
  • September 22, 2020
  • 1